The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
News
Advertisement
An independent Data Safety and Monitoring Board has recommended that the phase 1 RePAIR trial continue at an accelerated pace.
Advertisement
The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed upcoming new therapies for relapsing MS.
Two sites in California and Missouri are actively recruiting patients with r/r LBCL who were treated with tisagenlecleucel to receive efineptakin alfa in the study.
Beam Therapeutics will assess the safety and efficacy of BEAM-101 for SCD in the phase 1/2 BEACON-101 study.
ALSFRS-R and FVC values were stable 3 months after treatment but significantly decreased 6 months after treatment, warranting further investigation.
Advertisement
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.
New treatment options expand management of relapsed or refractory disease.
Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
CYNK-101 is set to be evaluated in combination with standard chemotherapy, trastuzumab and pembrolizumab in a phase 1/2a study.
Advertisement
The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
The study is aiming to gain insight into glaucoma in African American populations.
CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.
The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed he utility of CAR T-cell therapy in late relapsed multiple myeloma.
Review top news and interview highlights from the week ending November 26, 2021.
The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.
The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s ex-vivo and in-vivo gene therapy platforms.
Pfizer and Sangamo voluntarily paused the trial after participants experienced FVIII activity levels of over 150%.
The professor from National Taiwan University Hospital discussed the benefits of delivering gene therapy directly to the putamen in AADC deficiency.
The designation follows durable responses seen in a phase 1 study of the agent.
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.
The investigational gene therapy, which will receive priority review, has a PDUFA date of May 20, 2022.
From baseline, all participants showed improvements on CGI-Improvement scale scores while all but 1 patient demonstrated improvement on modified Hoehn and Yahr scores.
The recommended phase 2 dose of cilta-cel elicited deep and durable responses, along with a tolerable safety profile.
Positive data has been seen with CAR T-cell therapy in patients with indolent lymphoma.
The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.
Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
A 1-stage factor VIII assay revealed no apparent decrease in factor VIII activity over time.
Review top news and interview highlights from the week ending November 19, 2021.
